Amniotic Allografts vs. Cellular Tissue Products: A Cost-of-Closure Analysis

Purchasing decisions in wound care are frequently made on a single-graft price sheet. That framing systematically misvalues categories that close wounds in fewer applications. The correct decision metric is cost per closed wound:

Cost per closed wound = (unit price × applications to closure) + (unit price × trim wastage %) + application labor cost

Category primer

• Amniotic allografts (dHACM, cryopreserved amnion, dual-layer amnion/chorion). HCT/Ps under 21 CFR Part 1271 ^[1]. Sold in discrete sizes; low prep overhead; typical DFU closure in 3–6 weekly applications in published trials ^[2].
• Cellular / tissue-based products (CTPs). Includes bilayered living-cell constructs (e.g., Apligraf) and dermal fibroblast constructs (e.g., Dermagraft). Higher per-application unit price, cold-chain shipping, short in-use windows. Typical DFU closure in 5–8+ applications in published trials ^[3].

Why per-graft price is misleading

Because CTPs typically ship in large single sizes, trim waste on a small wound can approach 40–60 % of the graft, driving effective cost-per-cm² sharply upward. Amniotic products sold in a tight size ladder (1×1 to 4×4 cm) largely eliminate that waste.

Actual dollar values depend on the current CMS ASP file and each facility''s contracted price ^[4]; the point is that a low sticker price with 6 applications and 40 % waste often costs more per closed wound than a higher sticker price with 4 applications and 10 % waste.

Non-price factors

• Storage. CTPs typically require validated cold chain and short in-use windows. Amniotic dHACM is ambient shelf-stable.
• Scheduling. CTP delivery windows constrain scheduling; missed windows waste the graft.
• Documentation burden. Both require the same MAC LCD documentation, but CTPs sometimes have narrower coverage indications.

How to build your own model

1. Pull your last 12 months of DFU / VLU cases treated with skin substitutes.
2. For each category, calculate mean applications to closure and mean trim waste.
3. Multiply by current contracted price per cm².
4. Add per-application labor cost.
5. Compare cost per closed wound.

FAQ

Are amniotic allografts always cheaper per closed wound than CTPs?

Not always, but often — because of fewer applications and lower trim waste. A rigorous internal analysis using your own case data is the only reliable answer for your practice.

Do payers care about cost per closed wound?

Increasingly, yes. Some MAC LCDs and value-based arrangements evaluate episode-level cost, not per-application cost ^[5].

What about outcomes beyond closure — recurrence?

Recurrence rates at 12 months are similar across both categories in published follow-up data, and are more strongly determined by offloading, glycemic control, and patient adherence than by product choice.

Which category has more supply-chain risk?

CTPs, because of cold-chain requirements and shorter shelf life. Amniotic dHACM has multi-year ambient shelf life and can be stocked to buffer supply disruptions.

How often should we rerun this model?

At least annually, and any time the CMS ASP file materially changes payment for a Q-code in your formulary ^[4].